
IDEXX Laboratories (IDXX) Stock Forecast & Price Target
IDEXX Laboratories (IDXX) Analyst Ratings
Bulls say
IDEXX Laboratories maintains a strong financial outlook, bolstered by an impressive customer retention rate of approximately 97%, which enhances revenue and earnings predictability. The company has achieved a compound annual growth rate (CAGR) of about 16% for organic consumables revenue from 2016 to 2022, indicating robust growth in its recurring consumables segment. Additionally, the expectation of increased clinical visits over the long term, combined with the potential for accelerated adoption of its testing products amid a recovering pet market, positions IDEXX for further market expansion.
Bears say
IDEXX Laboratories has experienced a consistent decline in clinical vet visits, with a year-over-year decrease of -1.7% reported in Q4'25, following similar declines in previous quarters, indicating a worrying trend in veterinary services. The company anticipates a further reduction of 200 basis points in pet visits for 2026, largely attributed to economic challenges facing lower-income pet owners, which could hinder demand for IDEXX’s diagnostic products and services. Additionally, financial hardships among customers and suppliers may exacerbate cash flow issues, potentially impacting sales and the overall growth of IDEXX's market presence.
This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.
IDEXX Laboratories (IDXX) Analyst Forecast & Price Prediction
Start investing in IDEXX Laboratories (IDXX)
Order type
Buy in
Order amount
Est. shares
0 shares